AbbVie has initiated a Phase 2 clinical trial for a forehead lines indication, signaling expansion of the Botox franchise beyond current FDA-cleared uses. The move comes as the company faces biosimilar pressure from ABP-450 (AEON Biopharma) and seeks to defend market share through indication expansion.
Regulatory
AbbVie Launches Phase 2 Forehead Lines Study
Allergan Aesthetics expands neuromodulator pipeline beyond FDA-approved indications.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Botox forehead lines remain off-label—AbbVie is moving to formalize the indication.
Forehead lines remain a high-volume treatment in aesthetic practices, but the indication is not yet formally cleared for Botox. A successful Phase 2 readout could support a future 510(k) or supplemental BLA, potentially opening a new revenue stream and strengthening Allergan's competitive moat. The trial design and patient population will signal whether AbbVie is targeting primary-indication status or label expansion for existing users.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.